Last reviewed · How we verify
NCT05207878
Interhemispheric Connectivity and Compensation
NA trial testing STEGA-MRI in Peripheral Nerve Injury Upper Limb in 120 participants. Completed in 1 August 2025.
1 August 2025
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 120 |
| Start date | 9 December 2021 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- STEGA-MRI
Conditions studied
- Peripheral Nerve Injury Upper Limb — all drugs for Peripheral Nerve Injury Upper Limb →
- Healthy — all drugs for Healthy →
Sponsor
Washington University School of Medicine
Who can join
18 and older, any sex, with Peripheral Nerve Injury Upper Limb or Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to determine which parts of the brain make it possible for some people to move skillfully with their left non-dominant hand.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Reducing Inter-Individual Differences in Task fMRI Preprocessing with OGRE (One-Step General Registration and Extraction) Preprocessing.
McAvoy MP, Liu L, Zhou R, Philip BA. · · 2025 · PMID 41026289 · DOI 10.1007/s12021-025-09741-6
Verify or expand the search:
- PubMed search for NCT05207878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Nerve Injury Upper Limb
Currently open trials in the same condition.
- NCT06616025 — This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Ex · Phase 3 · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05207878 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 9 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing